Literature DB >> 12419015

Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices.

A B Renwick1, S E Ball, J M Tredger, R J Price, D G Walters, J Kao, J A Scatina, B G Lake.   

Abstract

1. The effect of cimetidine on the metabolism of zaleplon (ZAL) in human liver subcellular fractions and precision-cut liver slices was investigated. 2. ZAL was metabolized to a number of products including 5-oxo-ZAL (M2), which is known to be formed by aldehyde oxidase, N-desethyl-ZAL (DZAL), which is known to be formed by CYP3A forms, and N-desethyl-5-oxo-ZAL (M1). 3. Human liver microsomes catalysed the NADPH-dependent metabolism of ZAL to DZAL. Kinetic analysis of three microsomal preparations revealed mean (+/-SEM) S(50) and V(max) of 310 +/- 24 micro M and 920 +/- 274 pmol/min/mg protein, respectively. 4. Human liver cytosol preparations catalysed the metabolism of ZAL to M2. Kinetic analysis of three cytosol preparations revealed mean (+/-SEM), K(m) and V(max) of 124 +/- 14 micro M and 564 +/- 143 pmol/min/mg protein, respectively. 5. Cimetidine inhibited ZAL metabolism to DZAL in liver microsomes and to M2 in the liver cytosol. With a ZAL substrate concentration of 62 micro M, the calculated mean (+/-SEM, n = 3) IC50 were 596 +/- 103 and 231 +/- 23 micro M for DZAL and M2 formation, respectively. Kinetic analysis revealed that cimetidine was a competitive inhibitor of M2 formation in liver cytosol with a mean (+/-SEM, n = 3) K(i) of 155 +/- 16 micro M. 6. Freshly cut human liver slices metabolized ZAL to a number of products including 1, M2 and DZAL. 7. Cimetidine inhibited ZAL metabolism in liver slices to M1 and M2, but not to DZAL. Kinetic analysis revealed that cimetidine was a competitive inhibitor of M2 formation in liver slices with an average (n = 2 preparations) K(i) of 506 micro M. 8. The results demonstrate that cimetidine can inhibit both the CYP3A and aldehyde oxidase pathways of ZAL metabolism in the human liver. Cimetidine appears to be a more potent inhibitor of aldehyde oxidase than of CYP3A forms and hence in vivo is likely to have a more marked effect on ZAL metabolism to M2 than on DZAL formation. 9. The results also demonstrate that precision-cut liver slices may be a useful model system for in vitro drug-interaction studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419015     DOI: 10.1080/00498250210158221

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

Review 1.  Structure, dynamics and selectivity in the sulfotransferase family.

Authors:  Thomas S Leyh; Ian Cook; Ting Wang
Journal:  Drug Metab Rev       Date:  2013-09-11       Impact factor: 4.518

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

3.  The gate that governs sulfotransferase selectivity.

Authors:  Ian Cook; Ting Wang; Steven C Almo; Jungwook Kim; Charles N Falany; Thomas S Leyh
Journal:  Biochemistry       Date:  2012-12-28       Impact factor: 3.162

Review 4.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  The mammalian aldehyde oxidase gene family.

Authors:  Enrico Garattini; Maddalena Fratelli; Mineko Terao
Journal:  Hum Genomics       Date:  2009-12       Impact factor: 4.639

6.  ecoAO: A Simple System for the Study of Human Aldehyde Oxidases Role in Drug Metabolism.

Authors:  Erickson M Paragas; Sara C Humphreys; Joshua Min; Carolyn A Joswig-Jones; Silke Leimkühler; Jeffrey P Jones
Journal:  ACS Omega       Date:  2017-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.